Literature DB >> 33574349

Correlation of staging and risk factors with cardiovascular autonomic neuropathy in patients with type II diabetes mellitus.

Muhanad M Dhumad1, Farqad B Hamdan2, Mahmood S Khudhair3, Hisham Y Al-Matubsi4.   

Abstract

The impairment of cardiovascular autonomic control among the underdiagnosed complication of diabetes mellitus (DM) with a high prevalence rate of up to 60% in type 2 DM (T2DM). Cardiac autonomic neuropathy (CAN) is an independent risk factor for cardiovascular mortality, arrhythmia, silent ischemia, any major cardiovascular event, and heart failure. We aimed to evaluate cardiovascular autonomic activity by different physiological maneuvers, study risk factors for diabetic CAN including age, gender, duration of diabetes, body mass index (BMI), and glycemic control, and correlate CAN stage with risk factors. One hundred and forty-two T2DM patients consisted of 62 males and 80 females and 100 volunteers as a control sample. Cardiac autonomic functions were assessed by Ewing's tests. Glycated hemoglobin (HbA1c), body weight, height, body mass index (BMI), and waist-hip ratio (WHR) were also measured. Cardiovascular autonomic functions and Ewing scores were significantly different in people with diabetes when compared with control healthy subjects. Ewings test values and Ewing scores were significantly different between diabetics with and without CAN and within patients with different CAN staging. People with diabetes with CAN have a significantly longer duration of disease when compared to those without CAN. A strong association has been found between CAN severity and patient age, duration of disease, HbA1c severity, and the WHR (P < 0.001) but not with BMI. The duration of disease and HbA1c level appear to be associated with the development of CAN (P = 0.001 and P = 0.008, respectively). The poorer glycemic control and the longer the duration of the disease, the higher the prevalence of CAN in T2DM. Age, duration of disease, WHR, and HbA1c are well correlated with the severity of CAN. Parasympathetic impairment is more sensitive to the detection of autonomic dysfunctions than do sympathetic impairment.

Entities:  

Year:  2021        PMID: 33574349     DOI: 10.1038/s41598-021-80962-w

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  29 in total

1.  JAMA PATIENT PAGE. Diabetic Neuropathy.

Authors:  Aria A Razmaria
Journal:  JAMA       Date:  2015-11-24       Impact factor: 56.272

2.  Increased prevalence of cardiac autonomic dysfunction at different degrees of glucose intolerance in the general population: the KORA S4 survey.

Authors:  Dan Ziegler; Andreas Voss; Wolfgang Rathmann; Alexander Strom; Siegfried Perz; Michael Roden; Annette Peters; Christa Meisinger
Journal:  Diabetologia       Date:  2015-02-28       Impact factor: 10.122

3.  Definition, Classification and Diagnosis of Diabetes, Prediabetes and Metabolic Syndrome.

Authors:  Zubin Punthakee; Ronald Goldenberg; Pamela Katz
Journal:  Can J Diabetes       Date:  2018-04       Impact factor: 4.190

4.  Cardiovascular autonomic neuropathy in diabetes: clinical impact, assessment, diagnosis, and management.

Authors:  Vincenza Spallone; Dan Ziegler; Roy Freeman; Luciano Bernardi; Simona Frontoni; Rodica Pop-Busui; Martin Stevens; Peter Kempler; Jannik Hilsted; Solomon Tesfaye; Phillip Low; Paul Valensi
Journal:  Diabetes Metab Res Rev       Date:  2011-10       Impact factor: 4.876

Review 5.  Recommendations for the use of cardiovascular tests in diagnosing diabetic autonomic neuropathy.

Authors:  V Spallone; F Bellavere; L Scionti; S Maule; R Quadri; G Bax; P Melga; G L Viviani; K Esposito; R Morganti; P Cortelli
Journal:  Nutr Metab Cardiovasc Dis       Date:  2011-01       Impact factor: 4.222

6.  Association between cardiovascular autonomic neuropathy and left ventricular dysfunction: DCCT/EDIC study (Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications).

Authors:  Rodica Pop-Busui; Patricia A Cleary; Barbara H Braffett; Catherine L Martin; William H Herman; Phillip A Low; Joao A C Lima; David A Bluemke
Journal:  J Am Coll Cardiol       Date:  2012-12-19       Impact factor: 24.094

Review 7.  Cardiac autonomic neuropathy: Risk factors, diagnosis and treatment.

Authors:  Victoria A Serhiyenko; Alexandr A Serhiyenko
Journal:  World J Diabetes       Date:  2018-01-15

Review 8.  Diabetic Neuropathy: A Position Statement by the American Diabetes Association.

Authors:  Rodica Pop-Busui; Andrew J M Boulton; Eva L Feldman; Vera Bril; Roy Freeman; Rayaz A Malik; Jay M Sosenko; Dan Ziegler
Journal:  Diabetes Care       Date:  2017-01       Impact factor: 19.112

9.  Diabetic cardiac autonomic neuropathy, inflammation and cardiovascular disease.

Authors:  Aaron I Vinik; Tomris Erbas; Carolina M Casellini
Journal:  J Diabetes Investig       Date:  2013-01-29       Impact factor: 4.232

10.  Association between impaired cardiovascular autonomic function and hypoglycemia in patients with type 1 diabetes.

Authors:  Mamta Jaiswal; Katherine McKeon; Nicholas Comment; James Henderson; Scott Swanson; Cynthia Plunkett; Patrick Nelson; Rodica Pop-Busui
Journal:  Diabetes Care       Date:  2014-06-27       Impact factor: 19.112

View more
  3 in total

1.  Device for Controlling Stimulus Self-Application During Autonomic Nervous System Tests.

Authors:  Marek Żyliński; Wiktor Niewiadomski; Gerard Cybulski; Anna Gąsiorowska
Journal:  Med Devices (Auckl)       Date:  2021-06-01

2.  Cardiovascular autonomic neuropathy in people with type 2 diabetes mellitus; investigation of its association with classical cardiovascular risk factors using cardiovascular autonomic reflex tests: a cross-sectional study.

Authors:  Ahmad Osailan
Journal:  Egypt Heart J       Date:  2021-05-13

3.  Age and Disease Duration Independent Cardiac Autonomic Neuropathy in Patients with Diabetic Foot Complications: Case-Control Study.

Authors:  Sarthak Wadhera; Ashu Rastogi; Pinaki Dutta; Ankur Gupta; Sanjay K Bhadada
Journal:  Indian J Endocrinol Metab       Date:  2022-09-20
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.